


**Supplementary Figure A. Clinical outcomes among patients receiving standard treatment.** Kaplan-Meier plots show (A) disease-free survival, (B) recurrence-free survival and (C) overall survival for patients receive standard treatment. Abbreviations: EC-T, epirubicin and cyclophosphamide followed by docetaxel; No, Number.




**Supplementary Figure B. Efficacy of the integrated mRNA-lncRNA signature and traditional clinicopathologic factors in determination of prognosis in the high-risk (arm B) and low-risk patients (arm C) receiving the same standard treatment.** Time-dependent receiver operating curves for (A) disease-free survival (DFS), (B) recurrence-free survival (RFS) and (C) overall survival (OS) were plotted with AUCs reported. All factors were coded as categorical variables.

**Supplementary Table A. Participating centers.**

| Number | Hospital |
|---|---|
| 1 | Fudan University Shanghai Cancer Center |
| 2 | Chongqing Cancer Hospital, Chongqing University |
| 3 | Northern Jiangsu People's Hospital |
| 4 | Fujian Medical University Union Hospital |
| 5 | Shanghai First Maternity and Infant Hospital |
| 6 | Obstetrics and Gynecology Hospital of Fudan University |
| 7 | The International Peace Maternity & Child Health Hospital of China Welfare Institute |

**Supplementary Table B. Treatment cycles and dose modifications between arm A and arm B in high-risk patients.**

| | Arm A (n = 163) | Arm B (n = 169) | Difference (95% CI) |
|---|---|---|---|
| | TEC-GP | EC-T | |
| | N (%) | N (%) | |
| Patients who completed all planned cycles of treatment | 149 (91) | 158 (93) | -2 (-8 to 4) |
| Any treatment-related adverse events (TRAEs) | 163 (100) | 169 (100) | 0 (-2 to 2) |
| Any ≥3 TRAEs | 105 (64) | 86 (51) | 13 (3 to 24) |
| Treatment-related SAEs | 9 (6) | 7 (4) | 2 (-4 to 6) |
| Any TRAEs leading to dose delayed | 47 (29) | 33 (20) | 9 (0 to 18) |
| Any TRAEs leading to dose reduction | 51 (31) | 25 (15) | 16 (7 to 25) |
| Any TEAEs leading to drug permanently discontinued | 8 (5) | 5 (3) | 2 (-3 to 7) |

Abbreviations: CI, confidence interval; EC-T, epirubicin and cyclophosphamide followed by docetaxel; TEC-GP, docetaxel, epirubicin, and cyclophosphamide followed by gemcitabine and cisplatin. SAE, severe adverse event. TRAE, Treatment-related adverse event.